Cancer care 2025: an overview of cancer outcomes data across Europe
Despite data showing that cancer is on track to become the leading cause of death in the European Union (EU) by 2035, encouraging signs are emerging.
The first in depth look at cancer comparisons since 2019 by The Swedish Institute for Health Economics’ (IHE) new report shows that the number of cancer deaths is stabilizing, with 12 EU countries seeing a decline in deaths (per 100,000), signalling a turning point in the fight against the disease. Overall, cancer deaths in Europe have stabilized at around 1.3-1.4 million annually since 2008.
The research shows that cancer survival rates have improved across Europe, but disparities between countries – as well as types of cancers – remain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze